SHC016V
MISSION® pLKO.1-puro Non-Target shRNA Control Transduction Particles
Targets no known genes from any species
Synonym(s):
MISSION®, MISSION® Control Transduction Particles, negative control, negative shRNA control, non-target control, non-target shRNA, non-target shRNA control, shRNA control
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41106609
NACRES:
NA.51
Quality Level
100
200
product line
MISSION®
concentration
≥1x106 VP/ml (via p24 assay)
shipped in
dry ice
storage temp.
−70°C
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
The MISSION® pLKO.1-puro Non-Target shRNA Control Transduction Particles contain an shRNA insert that does not target any known genes from any species, making it useful as a negative control in experiments using the MISSION® shRNA library clones. This allows one to examine the effect of transduction of a short-hairpin on gene expression and interpret the knockdown effect seen with shRNA clones. Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The Non-Target shRNA Control Transduction Particles are provided as 200 μL at 1 x 106 TU/mL via p24 assay.
When conducting experiments using MISSION® shRNA clones, the proper controls should be a key element of your experimental design to allow for accurate interpretation of knockdown results. The MISSION Control Transduction Particles are a critical positive control to monitor transduction efficiency.
To see more application data, protocols, vector maps visit sigma.com/shrna.
To see more application data, protocols, vector maps visit sigma.com/shrna.
Application
MISSION® pLKO.1-puro Non-Target shRNA Control Transduction Particles have been used to generate 3T3-L1 (pre-adipocytes) control cell lines.
Analysis Note
To see more application data, protocols, vector maps visit sigma.com/shrna.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
recommended
Product No.
Description
Pricing
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
SIRT6 Depletion Suppresses Tumor Growth by Promoting Cellular Senescence Induced by DNA Damage in HCC.
Lee N
PLoS ONE, 11(11), e0165835-e0165835 (2016)
Natsumi Suzuki et al.
Oncogene, 39(10), 2202-2211 (2019-12-13)
p53 is one of the most important tumor suppressor genes, and the exploration of p53-target genes is important for elucidation of its functional mechanisms. In this study, we identified Armadillo Repeat gene deleted in Velo-Cardio-Facial syndrome (ARVCF) as a direct
Esperanza Martín-Sánchez et al.
PloS one, 9(11), e112148-e112148 (2014-11-12)
Currently, there is no efficient therapy for patients with peripheral T cell lymphoma (PTCL). The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are important mediators of cell survival. We aimed to determine the therapeutic value of PIM
Jessica B Casaletto et al.
Proceedings of the National Academy of Sciences of the United States of America, 116(15), 7533-7542 (2019-03-23)
Activation of the Met receptor tyrosine kinase, either by its ligand, hepatocyte growth factor (HGF), or via ligand-independent mechanisms, such as MET amplification or receptor overexpression, has been implicated in driving tumor proliferation, metastasis, and resistance to therapy. Clinical development
Zilong Yan et al.
Journal of cancer research and clinical oncology, 145(5), 1147-1164 (2019-02-17)
This study aimed at investigating the function and significance of CD110 expression in pancreatic cancer. We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer. We evaluated clinical outcomes and other clinicopathological factors to
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service